Abstract: A gold(III) complex of formula (I) or formula (II) wherein R1 and R2 are each independently a hydrogen, an optionally substituted alkyl, an optionally substituted cycloalkyl, an optionally substituted arylalkyl, or an optionally substituted aryl; R3 and R4 are each independently a hydrogen, an optionally substituted alkyl, an optionally substituted cycloalkyl, an optionally substituted arylalkyl, an optionally substituted aryl, an optionally substituted heterocyclyl, an optionally substituted alkoxy, a hydroxyl, a halo, a nitro, a cyano, a N-monosubstituted amino group, or a N,N-disubstituted amino group; and X is Cl, Br, or I. A pharmaceutical composition containing the gold(III) complex of formula (I) or (II), and a method of treating cancer are included.

Abstract: A gold(III) complex of formula (I) or formula (II) wherein R1 and R2 are each independently a hydrogen, an optionally substituted alkyl, an optionally substituted cycloalkyl, an optionally substituted arylalkyl, or an optionally substituted aryl; R3 and R4 are each independently a hydrogen, an optionally substituted alkyl, an optionally substituted cycloalkyl, an optionally substituted arylalkyl, an optionally substituted aryl, an optionally substituted heterocyclyl, an optionally substituted alkoxy, a hydroxyl, a halo, a nitro, a cyano, a N-monosubstituted amino group, or a N,N-disubstituted amino group; and X is Cl, Br, or I. A pharmaceutical composition containing the gold(III) complex of formula (I) or (II), and a method of treating cancer are included.

Abstract: The present invention relates to a gold complex having a compound of formula (I) as anticancer or chemotherapeutic agent. The present invention also relates to method of preparation of such complexes, pharmaceutical compositions containing such complexes and further extends to a method of treating or diagnosing a subject/patient suffering from cancer using such complexes.

Abstract: Systems and methods for remote command access in a hybrid cloud to on-premises devices are described. An example method includes receiving, by a gateway service, a request for a connection between a remote support service agent and an on-premises device. The method further includes receiving, by the gateway service, consent from an authorized user associated with the on-premises device. The method further includes creating, by the gateway service, a first session with the on-premises device, where a scope of the consent is limited to the first session. The method further includes provisioning, by the gateway service, a device-specific hybrid connection endpoint for the first session. The method further includes forming, by the gateway service a secure session by binding the device-specific hybrid connection endpoint with a second session, the secure session allowing for transport of data and a set of commands based on a scope of the consent.

Abstract: A platinum(II) complex of formula (I), or a pharmaceutically acceptable solvate or tautomer thereof, wherein R1 and R2 are each independently a hydrogen, an optionally substituted alkyl, an optionally substituted cycloalkyl, an optionally substituted arylalkyl, or an optionally substituted aryl; or wherein R1 and R2 together form a five-, six-, or seven-membered ring with the nitrogen atoms to which they are attached; and X is a nitrate anion, a hexafluorophosphate anion, a hexafluoroantimonate anion, a trifluoromethanesulfonate anion, a tetrafluoroborate anion, a perchlorate anion, or a halide anion. A pharmaceutical composition containing the platinum(II) complex of formula (I), and a method of treating cancer are also disclosed.

Abstract: The invention is directed to a method of treatment of proliferative diseases or disorders such as cancer with gold(I) N-heterocyclic carbene (NHC) thiourea or substituted thiourea complexes, to the complexes per se and to therapeutic compositions containing these gold(I) based complexes.

Abstract: The invention is directed to a method of treatment of proliferative diseases or disorders such as cancer with gold(I) N-heterocyclic carbene (NHC) thiourea or substituted thiourea complexes, to the complexes per se and to therapeutic compositions containing these gold(I) based complexes.

Abstract: The invention is directed to a method of treatment of proliferative diseases or disorders such as cancer with gold(I) N-heterocyclic carbene (NHC) thiourea or substituted thiourea complexes, to the complexes per se and to therapeutic compositions containing these gold(I) based complexes.

Abstract: A gold(III) complex of formula (I) or formula (II) wherein R1 and R2 are each independently a hydrogen, an optionally substituted alkyl, an optionally substituted cycloalkyl, an optionally substituted arylalkyl, or an optionally substituted aryl; R3 and R4 are each independently a hydrogen, an optionally substituted alkyl, an optionally substituted cycloalkyl, an optionally substituted arylalkyl, an optionally substituted aryl, an optionally substituted heterocyclyl, an optionally substituted alkoxy, a hydroxyl, a halo, a nitro, a cyano, a N-monosubstituted amino group, or a N,N-disubstituted amino group; and X is Cl, Br, or I. A pharmaceutical composition containing the gold(III) complex of formula (I) or (II), and a method of treating cancer are included.

Abstract: A gold(III) complex of formula (I) or formula (II) wherein R1 and R2 are each independently a hydrogen, an optionally substituted alkyl, an optionally substituted cycloalkyl, an optionally substituted arylalkyl, or an optionally substituted aryl; R3 and R4 are each independently a hydrogen, an optionally substituted alkyl, an optionally substituted cycloalkyl, an optionally substituted arylalkyl, an optionally substituted aryl, an optionally substituted heterocyclyl, an optionally substituted alkoxy, a hydroxyl, a halo, a nitro, a cyano, a N-monosubstituted amino group, or a N,N-disubstituted amino group; and X is Cl, Br, or I. A pharmaceutical composition containing the gold(III) complex of formula (I) or (II), and a method of treating cancer are included.

Abstract: A gold(III) complex of formula (I) or formula (II) wherein R1 and R2 are each independently a hydrogen, an optionally substituted alkyl, an optionally substituted cycloalkyl, an optionally substituted arylalkyl, or an optionally substituted aryl; R3 and R4 are each independently a hydrogen, an optionally substituted alkyl, an optionally substituted cycloalkyl, an optionally substituted arylalkyl, an optionally substituted aryl, an optionally substituted heterocyclyl, an optionally substituted alkoxy, a hydroxyl, a halo, a nitro, a cyano, a N-monosubstituted amino group, or a N,N-disubstituted amino group; and X is Cl, Br, or I. A pharmaceutical composition containing the gold(III) complex of formula (I) or (II), and a method of treating cancer are included.

Abstract: Mixed ligand phosphinogold(I) complexes as anticancer agents. The gold(I) ion of the complexes is coordinated to a phosphine and a dithiocarbamate or halogen ligand. Also described are a pharmaceutical composition incorporating the phosphinogold(I) complex, a method of synthesizing the phosphinogold(I) complex, and a method of treating cancer. The phosphinogold(I) complexes exhibit potent cytotoxicity against lung, cervical, and liver cancer cells.

Abstract: Mixed ligand phosphinogold(I) complexes as anticancer agents. The gold(I) ion of the complexes is coordinated to a phosphine and a dithiocarbamate or halogen ligand. Also described are a pharmaceutical composition incorporating the phosphinogold(I) complex, a method of synthesizing the phosphinogold(I) complex, and a method of treating cancer. The phosphinogold(I) complexes exhibit potent cytotoxicity against lung, cervical, and liver cancer cells.

Abstract: A platinum(II) complex of formula (I), or a pharmaceutically acceptable solvate or tautomer thereof, wherein R1 and R2 are each independently a hydrogen, an optionally substituted alkyl, an optionally substituted cycloalkyl, an optionally substituted arylalkyl, or an optionally substituted aryl; or wherein R1 and R2 together form a five-, six-, or seven-membered ring with the nitrogen atoms to which they are attached; and X is a nitrate anion, a hexafluorophosphate anion, a hexafluoroantimonate anion, a trifluoromethanesulfonate anion, a tetrafluoroborate anion, a perchlorate anion, or a halide anion. A pharmaceutical composition containing the platinum(II) complex of formula (I), and a method of treating cancer are also disclosed.

Abstract: A family of platinum(II) complex with mixed ligands as anticancer agents. The platinum(II) ion is coordinated to dicyclopentadiene and dithiocarbamate ligands. Also described are a pharmaceutical composition incorporating the platinum(II) complex, a methods of synthesizing the platinum(II) complex, and a method of treating cancer. The platinum(II) complexes exhibit potent cytotoxicity against lung and cervical cancer cell lines as well as low nephrotoxicity.

Abstract: A gold(III) complex of formula (I) or formula (II) wherein R1 and R2 are each independently a hydrogen, an optionally substituted alkyl, an optionally substituted cycloalkyl, an optionally substituted arylalkyl, or an optionally substituted aryl; R3 and R4 are each independently a hydrogen, an optionally substituted alkyl, an optionally substituted cycloalkyl, an optionally substituted arylalkyl, an optionally substituted aryl, an optionally substituted heterocyclyl, an optionally substituted alkoxy, a hydroxyl, a halo, a nitro, a cyano, a N-monosubstituted amino group, or a N,N-disubstituted amino group; and X is Cl, Br, or I. A pharmaceutical composition containing the gold(III) complex of formula (I) or (II), and a method of treating cancer are included.

Abstract: The invention is directed to a method of treatment of proliferative diseases or disorders such as cancer with gold(I) N-heterocyclic carbene (NHC) thiourea or substituted thiourea complexes, to the complexes per se and to therapeutic compositions containing these gold(I) based complexes.

Abstract: The invention is directed to a method of treatment of proliferative diseases or disorders such as cancer with gold(I) N-heterocyclic carbene (NHC) thiourea or substituted thiourea complexes, to the complexes per se and to therapeutic compositions containing these gold(I) based complexes.

Abstract: The invention is directed to a method of treatment of proliferative diseases or disorders such as cancer with gold(I) N-heterocyclic carbene (NHC) thiourea or substituted thiourea complexes, to the complexes per se and to therapeutic compositions containing these gold(I) based complexes.

Abstract: The invention is directed to platinum(II) complexes comprising dithiocarbamates and methods for treating cancer using these complexes.